Gaithersburg, Md.—December 2, 2015 — VLP Therapeutics, LLC. (“VLP”), a Gaithersburg-based biotechnology company focusing on the research and development of therapeutic and preventative vaccines and next generation antibody agents based upon a novel and proprietary vaccine technology, announced that its Chief Executive Officer, Dr. Wataru Akahata, was invited to speak at the 2015 Dasan Conference in Busan, Korea on Wednesday, December 2, 2015, at 3:00 p.m. Local Time. The event, which is hosted by the Korean Federation of Science and Technology Societies (KOFST) is titled “the Development of Novel Technology for the Preparedness of Emerging and Unknown Infectious Diseases”and take place at Saintmare, Busan, Korea.

The following will be presented by Dr. Akahata at the Conference:
“Development of Novel Malaria and Dengue Virus-Like Particle Vaccines”
Wednesday, November 2, 2015, 3:00pm – 3:40pm Local Time

About VLP Therapeutics
VLP Therapeutics, LLC (VLP) was established in 2012 by seasoned biopharmaceutical veterans with mission to develop innovative medical treatment which transforms traditional vaccine and targeted antibody therapies to address global unmet medical needs. Its vision is to combat the 21st century global public health problems through revolutionary next generation i-αVLP (inserted alpha VLP) technology platform. VLP is currently developing preventative and therapeutic vaccines as well as next generation of targeted antibody agents to treat cancer, infectious diseases, auto-immune diseases and neurological diseases.

For more information, please visit